ProStop Implant for Hyperpronated Foot
ProStop Implant for Hyperpronated Foot
The objective of the registry is to evaluate the continued safety and performance of the
 Arthrex ProStop® implant used to treat hyperpronated foot.
To assess safety, related adverse events will be evaluated at six months postoperative and at
 one-year postoperative time points. To evaluate performance, physical exam and imaging of the
 target area of the body will be evaluated at three months postoperative. Additionally,
 patient reported outcomes will be evaluated at three months postoperative, six months
 postoperative and one year postoperative using the Visual Analogue Scale (VAS), Veterans Rand
 12-Item Health Survey (VR-12) and Foot and Ankle Ability Measures (FAAM).
Inclusion Criteria:

 1. Subject requires surgery for treatment of hyperpronated foot using the Arthrex
 ProStop® implant

 2. Age >2 to 17 years

 3. Subject is not pregnant, nursing, prisoner, or ward of the state

 4. Subject or subject's representative signed informed consent and assent when,
 applicable, and is willing and able to comply with all study requirements

 Exclusion Criteria:

 1. Insufficient quantity or quality of bone.

 2. Blood supply limitations and previous infections, which may retard healing.

 3. Foreign-body sensitivity.

 4. Any active infection or blood supply limitations.

 5. Conditions that tend to limit the patient's ability or willingness to restrict
 activities or follow directions during the healing period.